The most convincing evidence for an etiological role of cysteinyl-LTs in asthma comes from the therapeutic efficacy of CysLT __number__ receptor antagonists (e.g., montelukast, zafirlukast, pranlukast), commonly known as leukotriene receptor antagonists (LTRAs), and __number__ -lipoxygenase ( __number__ -LO) inhibitors (e.g., zileuton) in patients with asthma [ __number__ ].